Ph.D. Michael Exton - 08 Jul 2024 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: LXRX
Reported as of: 08 Jul 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jul 2024, 17:27:00 UTC
Next SEC filing: 18 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Michael Exton, Ph.D.

Key filing fact

Ph.D. Michael Exton filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 08 Jul 2024.

Key facts

This page summarizes Ph.D. Michael Exton's Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Jul 2024, 17:27.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LXRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +1,675,000
Change %
Price: $0.000000
Shares after: 1,675,000
Date: 08 Jul 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,675,000
Exercise price: $1.67
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.